Cargando…
A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia
BACKGROUND: Acute myeloid leukemia (AML) is the most common malignancy of the hematological system, and there are currently a number of studies regarding abnormal alterations in energy metabolism, but fewer reports related to fatty acid metabolism (FAM) in AML. We therefore analyze the association o...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404605/ https://www.ncbi.nlm.nih.gov/pubmed/36002858 http://dx.doi.org/10.1186/s12944-022-01687-x |
_version_ | 1784773676911034368 |
---|---|
author | Zhang, Hai-Bin Sun, Zhuo-Kai Zhong, Fang-Min Yao, Fang-Yi Liu, Jing Zhang, Jing Zhang, Nan Lin, Jin Li, Shu-Qi Li, Mei-Yong Jiang, Jun-Yao Cheng, Ying Xu, Shuai Cheng, Xue-Xin Huang, Bo Wang, Xiao-Zhong |
author_facet | Zhang, Hai-Bin Sun, Zhuo-Kai Zhong, Fang-Min Yao, Fang-Yi Liu, Jing Zhang, Jing Zhang, Nan Lin, Jin Li, Shu-Qi Li, Mei-Yong Jiang, Jun-Yao Cheng, Ying Xu, Shuai Cheng, Xue-Xin Huang, Bo Wang, Xiao-Zhong |
author_sort | Zhang, Hai-Bin |
collection | PubMed |
description | BACKGROUND: Acute myeloid leukemia (AML) is the most common malignancy of the hematological system, and there are currently a number of studies regarding abnormal alterations in energy metabolism, but fewer reports related to fatty acid metabolism (FAM) in AML. We therefore analyze the association of FAM and AML tumor development to explore targets for clinical prognosis prediction and identify those with potential therapeutic value. METHODS: The identification of AML patients with different fatty acid metabolism characteristics was based on a consensus clustering algorithm. The CIBERSORT algorithm was used to calculate the proportion of infiltrating immune cells. We used Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis to construct a signature for predicting the prognosis of AML patients. The Genomics of Drug Sensitivity in Cancer database was used to predict the sensitivity of patient samples in high- and low-risk score groups to different chemotherapy drugs. RESULTS: The consensus clustering approach identified three molecular subtypes of FAM that exhibited significant differences in genomic features such as immunity, metabolism, and inflammation, as well as patient prognosis. The risk-score model we constructed accurately predicted patient outcomes, with area under the receiver operating characteristic curve values of 0.870, 0.878, and 0.950 at 1, 3, and 5 years, respectively. The validation cohort also confirmed the prognostic evaluation performance of the risk score. In addition, higher risk scores were associated with stronger fatty acid metabolisms, significantly higher expression levels of immune checkpoints, and significantly increased infiltration of immunosuppressive cells. Immune functions, such as inflammation promotion, para-inflammation, and type I/II interferon responses, were also significantly activated. These results demonstrated that immunotherapy targeting immune checkpoints and immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs) and M2 macrophages, are more suitable for patients with high-risk scores. Finally, the prediction results of chemotherapeutic drugs showed that samples in the high-risk score group had greater treatment sensitivity to four chemotherapy drugs in vitro. CONCLUSIONS: The analysis of the molecular patterns of FAM effectively predicted patient prognosis and revealed various tumor microenvironment (TME) characteristics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12944-022-01687-x. |
format | Online Article Text |
id | pubmed-9404605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94046052022-08-26 A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia Zhang, Hai-Bin Sun, Zhuo-Kai Zhong, Fang-Min Yao, Fang-Yi Liu, Jing Zhang, Jing Zhang, Nan Lin, Jin Li, Shu-Qi Li, Mei-Yong Jiang, Jun-Yao Cheng, Ying Xu, Shuai Cheng, Xue-Xin Huang, Bo Wang, Xiao-Zhong Lipids Health Dis Research BACKGROUND: Acute myeloid leukemia (AML) is the most common malignancy of the hematological system, and there are currently a number of studies regarding abnormal alterations in energy metabolism, but fewer reports related to fatty acid metabolism (FAM) in AML. We therefore analyze the association of FAM and AML tumor development to explore targets for clinical prognosis prediction and identify those with potential therapeutic value. METHODS: The identification of AML patients with different fatty acid metabolism characteristics was based on a consensus clustering algorithm. The CIBERSORT algorithm was used to calculate the proportion of infiltrating immune cells. We used Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis to construct a signature for predicting the prognosis of AML patients. The Genomics of Drug Sensitivity in Cancer database was used to predict the sensitivity of patient samples in high- and low-risk score groups to different chemotherapy drugs. RESULTS: The consensus clustering approach identified three molecular subtypes of FAM that exhibited significant differences in genomic features such as immunity, metabolism, and inflammation, as well as patient prognosis. The risk-score model we constructed accurately predicted patient outcomes, with area under the receiver operating characteristic curve values of 0.870, 0.878, and 0.950 at 1, 3, and 5 years, respectively. The validation cohort also confirmed the prognostic evaluation performance of the risk score. In addition, higher risk scores were associated with stronger fatty acid metabolisms, significantly higher expression levels of immune checkpoints, and significantly increased infiltration of immunosuppressive cells. Immune functions, such as inflammation promotion, para-inflammation, and type I/II interferon responses, were also significantly activated. These results demonstrated that immunotherapy targeting immune checkpoints and immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs) and M2 macrophages, are more suitable for patients with high-risk scores. Finally, the prediction results of chemotherapeutic drugs showed that samples in the high-risk score group had greater treatment sensitivity to four chemotherapy drugs in vitro. CONCLUSIONS: The analysis of the molecular patterns of FAM effectively predicted patient prognosis and revealed various tumor microenvironment (TME) characteristics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12944-022-01687-x. BioMed Central 2022-08-25 /pmc/articles/PMC9404605/ /pubmed/36002858 http://dx.doi.org/10.1186/s12944-022-01687-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zhang, Hai-Bin Sun, Zhuo-Kai Zhong, Fang-Min Yao, Fang-Yi Liu, Jing Zhang, Jing Zhang, Nan Lin, Jin Li, Shu-Qi Li, Mei-Yong Jiang, Jun-Yao Cheng, Ying Xu, Shuai Cheng, Xue-Xin Huang, Bo Wang, Xiao-Zhong A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia |
title | A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia |
title_full | A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia |
title_fullStr | A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia |
title_full_unstemmed | A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia |
title_short | A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia |
title_sort | novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404605/ https://www.ncbi.nlm.nih.gov/pubmed/36002858 http://dx.doi.org/10.1186/s12944-022-01687-x |
work_keys_str_mv | AT zhanghaibin anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT sunzhuokai anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT zhongfangmin anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT yaofangyi anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT liujing anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT zhangjing anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT zhangnan anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT linjin anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT lishuqi anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT limeiyong anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT jiangjunyao anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT chengying anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT xushuai anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT chengxuexin anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT huangbo anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT wangxiaozhong anovelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT zhanghaibin novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT sunzhuokai novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT zhongfangmin novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT yaofangyi novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT liujing novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT zhangjing novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT zhangnan novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT linjin novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT lishuqi novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT limeiyong novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT jiangjunyao novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT chengying novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT xushuai novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT chengxuexin novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT huangbo novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia AT wangxiaozhong novelfattyacidmetabolismrelatedsignatureidentifiesfeaturesofthetumormicroenvironmentandpredictsclinicaloutcomeinacutemyeloidleukemia |